8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 28, 2011

Merck & Co., Inc.

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

1-6571	22-1918501
(Commission File Number)	(I.R.S. Employer Identification No.)
One Merck Drive, PO Box 100, Whitehouse Station, NJ	08889-0100
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s Telephone Number, Including Area Code (908) 423-1000

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.

Incorporated by reference is a press release issued by the Registrant on February 3, 2011, regarding earnings for the fourth quarter of 2010, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.

This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 2.06. Material Impairments.

Vorapaxar is a thrombin receptor antagonist or antiplatelet protease activated receptor-1 inhibitor being studied for the prevention and treatment of thrombosis. Merck was studying vorapaxar in two major clinical endpoint trials to evaluate the investigational medicine for the prevention of cardiac events: TRACER, a study in patients with acute coronary syndrome which has ended, and TRA-2P (also known as TIMI 50), a study in patients with prior heart attack, stroke and peripheral artery disease which is continuing in large part. Both studies were designed as event-driven trials in which patients were planned to be followed for a minimum of one year, and both had completed enrollment. In January 2011, Merck announced that the combined Data and Safety Monitoring Board (DSMB) for the two studies had reviewed the available safety and efficacy data, and made recommendations for study changes to the chairpersons of the steering committees for the two studies. The study chairpersons agreed to implement these changes, and as a result: in the TRACER study, patients were to discontinue study drug and investigators were to begin to close out the study in a timely and orderly fashion. In the TRA-2P study, study drug was continued in patients who had experienced a previous heart attack or peripheral arterial disease (approximately 75% of the patients enrolled in the study), and was immediately discontinued in patients who experienced a stroke prior to entry into the study or during the course of the study. Merck subsequently announced that the chairman of the TRA-2P study reported to investigators that the DSMB had communicated that based on all of the data (safety and efficacy) available to them from both trials, they recommended that subjects with a history of stroke not receive vorapaxar. The DSMB had observed an increase in intracranial hemorrhage in patients with a history of stroke that is not outweighed by their considerations of potential benefit.

As a result of these developments, on January 28, 2011 the Company concluded that a fourth quarter 2010 pre-tax impairment charge of $1.7 billion related to the vorapaxar in process research and development intangible asset that was established as part of the Schering-Plough purchase price allocation was appropriate.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99.1	Press release issued February 3, 2011 regarding earnings for fourth quarter 2010
Exhibit 99.2	Certain supplemental information not included in the press release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Merck & Co., Inc.
Date: February 3, 2011	By:	/s/ Katie E. Fedosz
		KATIE E. FEDOSZ
		Senior Assistant Secretary

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release issued February 3, 2011 regarding earnings for fourth quarter 2010
99.2	Certain supplemental information not included in the press release

EX-99.1

Exhibit 99.1

News Release

Media Contacts:	David Caouette	Investor Contacts:	Alex Kelly
	(908) 423-3461		(908) 423-5185
	Steven Campanini		Joe Romanelli
	(908) 423-4291		(908) 423-5088

Merck Announces Fourth Quarter and Full Year 2010 Financial Results

• Company Reports Double-Digit Non-GAAP EPS Growth in the Fourth Quarter

• Fourth Quarter Non-GAAP EPS of $0.88, Excluding Certain Items; GAAP EPS of $(0.17); Full Year 2010 Non-GAAP EPS of $3.42, Excluding Certain Items; GAAP EPS of $0.28

• Continued Strong Global Growth from JANUVIA/JANUMET, SINGULAIR, ISENTRESS, REMICADE

• Realized More than $2 Billion in Net Synergy Savings in 2010; On Track to Reach $3.5 Billion in Annual Savings by End of 2012

• Company Withdraws Previous Long-Term Non-GAAP EPS Target; Full Year 2011 Non-GAAP EPS Target of $3.64 to $3.76, Excluding Certain Items; GAAP EPS Range of $2.05 to $2.33

WHITEHOUSE STATION, N.J., Feb. 3, 2011 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses. The purchase accounting adjustments include a $1.7 billion pre-tax charge related to its vorapaxar clinical research program. Fourth quarter GAAP EPS was $(0.17). Merck also announced full year 2010 non-GAAP EPS of $3.42, excluding certain items, and full year GAAP EPS of $0.28.

Worldwide sales for the fourth quarter of 2010 were $12.1 billion. GAAP net loss¹ for the fourth quarter was $531 million. For the full year of 2010, worldwide sales were $46.0 billion and GAAP net income was $861 million.

A reconciliation of EPS as reported in accordance with GAAP to non-GAAP EPS that excludes certain items is provided in the table that follows. The fourth quarter and full year 2009 results below include legacy Schering-Plough results only for the post-merger period, which began on Nov. 4, 2009.

¹ Net loss attributable to Merck & Co., Inc.

	Fourth Quarter 2010			Fourth Quarter 2009			Year Ended Dec. 31, 2010			Year Ended Dec. 31, 2009
GAAP EPS	$	(0.17	)	$	2.35		$	0.28		$	5.65
EPS difference2		1.05			(1.56	)		3.14			(2.40	)
Non-GAAP EPS that excludes certain items, listed below3	$	0.88		$	0.79		$	3.42		$	3.25
	Fourth Quarter 2010			Fourth Quarter 2009			Year Ended Dec. 31, 2010			Year Ended Dec. 31, 2009
Purchase accounting adjustments4	$	3,431		$	2,286		$	9,007		$	2,286
Merger restructuring program		298			1,460			1,795			1,460
Costs related to other restructuring programs		56			36			191			521
Merger-related costs		160			288			396			544
Legal reserve		—			—			950			—
Gain on AstraZeneca’s asset option exercise		—			—			(443	)		—
Gain associated with Merck/Schering-Plough partnership		—			(7,530	)		—			(7,530	)
Gain from sale of interest in Merial		—			(400	)		—			(3,163	)
Net decrease (increase) in income before taxes		3,945			(3,860	)		11,896			(5,882	)
Income tax (benefit) expense5		(658	)		(458	)		(2,042	)		390
Decrease (increase) in net income	$	3,287		$	(4,318	)	$	9,854		$	(5,492	)
EPS difference2	$	1.05		$	(1.56	)	$	3.14		$	(2.40	)

² Represents the difference between calculated GAAP EPS and calculated non-GAAP EPS, which may be different than the amount calculated by dividing the impact of the excluded items by the weighted average shares.

³ Merck is providing certain 2010 and 2009 non-GAAP information in the charts on this page and in the charts on pages 5 and 6 related to expenses that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP. For a description of the items, see Tables 2a and 2b, including the related footnotes, attached to this release.

⁴ Amounts for the fourth quarter and full year of 2010 reflect $2.2 billion and $2.4 billion, respectively, of in-process research and development impairment charges, including a charge of $1.7 billion to write-down the intangible asset related to vorapaxar recorded in conjunction with the merger. The remaining amounts in 2010 and the amounts in 2009 represent expenses for the amortization of intangible assets and amortization of purchase accounting adjustments to inventories recognized as a result of the merger.

⁵ Includes an estimated income tax (benefit) expense on the reconciling items. In addition, amounts for the full year of 2010 include a $391 million tax benefit from changes in a foreign entity’s tax rate, which resulted in a reduction in deferred tax liabilities on product intangibles recorded in conjunction with the merger, as well as a $147 million tax charge related to U.S. health care reform legislation.

Page 2

“Merck today reported a high quality fourth quarter characterized by strong revenue performance, significant cost reductions and double-digit earnings growth,” said Kenneth C. Frazier, president and chief executive officer. “These results clearly demonstrate the benefits of the post-merger Merck with our broader product portfolio, robust late-stage pipeline and expanded global footprint.

“Looking ahead, our focus will be on delivering sustainable, profitable top-line growth,” Frazier added. “To do that, Merck will continue to innovate, make disciplined investments in our business and continue to drive out inefficiencies in our operations. Coming out of our first year as a combined company, Merck employees in markets all over the world are energized and excited about capitalizing on the many new opportunities we have to bring value to patients, customers and shareholders.”

Select Business Highlights

• Merck is currently launching more than 10 medicines in key markets around the world.

• The company continues to make progress in its pipeline, including:

• Boceprevir, an investigational oral hepatitis C virus (HCV) protease inhibitor, was granted Priority Review status by the U.S. Food and Drug Administration (FDA) and accelerated assessment status by the European Union.

• The FDA accepted a new drug application for an investigational extended-release formulation of JANUMET (sitagliptin/metformin HCI).

• In the Phase III DEFINE study with Merck’s investigational CETP inhibitor, anacetrapib, patients with coronary heart disease or CHD risk equivalents showed no significant differences from placebo in the primary safety measures studied. In addition, at 24 weeks, anacetrapib decreased LDL-C (bad cholesterol) by 40 percent and increased HDL-C (good cholesterol) by 138 percent in patients already treated with a statin and at guideline-recommended LDL-C goal.

Page 3

• Top-line results for Phase III SUCCEED trial of ridaforolimus showed it met the primary endpoint in patients with metastatic soft-tissue or bone sarcomas.

• Also in the quarter, the company announced the results of the SHARP trial, which showed that VYTORIN (ezetimibe/simvastatin) significantly reduced major vascular events in patients with chronic kidney disease. The SHARP study is the first and only prospective clinical study in patients with chronic kidney disease to show that an LDL cholesterol-lowering medicine reduced major vascular and atherosclerotic events.

• Merck continued its commitment to develop biosimilars through an alliance with Parexel International Corporation.

• The company acquired SmartCells, Inc., a privately held company developing a glucose responsive insulin formulation potentially for the treatment of type 1 and type 2 diabetes.

• The company completed a $2 billion public offering of senior notes. Proceeds will be used for general corporate purposes.

Fourth Quarter and Full Year Sales Results

The following supplemental combined 2009 non-GAAP sales are adjusted to reflect a full quarter and a full year of legacy Merck and legacy Schering-Plough combined results. See Explanatory Note on page 12 of this release for further information.

	GAAP 4Q10		GAAP 4Q09		Adj. 4Q09		Supp. Comb. Non- GAAP 4Q09		GAAP FY10		GAAP FY09		Adj. FY09		Supp. Comb. Non- GAAP FY09
Total Sales	$	12,094	$	10,093	$	2,123	$	12,216	$	45,987	$	27,428	$	18,537	$	45,964
Human Health6		10,581		9,072		1,733		10,805		39,811		25,236		14,862		40,098
Animal Health		815		494		265		759		2,941		494		2,222		2,716
Consumer Care6		251		149		83		232		1,342		149		1,131		1,281
Other Revenues7		447		379		41		420		1,893		1,548		322		1,870

⁶ Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the U.S. and Canada. Consumer Care includes U.S. and Canada consumer product sales.

⁷ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales. Revenue from AstraZeneca LP recorded by Merck was $302 million in the fourth quarter and $1.3 billion for the full year of 2010.

Page 4

Fourth Quarter and Full Year Expense and Other Information

The fourth quarter and full year 2010 results below reflect the performance of the combined company. The increases in 2010 non-GAAP expenses are largely due to the inclusion of legacy Schering-Plough post-merger results.

The costs detailed below on a GAAP basis during the fourth quarter of 2010 totaled $12.7 billion and include $3.9 billion of purchase accounting adjustments, restructuring costs and merger-related costs.

On a full year 2010 GAAP basis, these costs totaled $43.6 billion and include $11.4 billion in purchase accounting adjustments, restructuring costs and merger-related costs. See below for 2009 comparable periods.

Fourth Quarter

			Included in expenses for the period
	GAAP		Purchase Accounting Adjustments4		Restructuring Costs			Merger- Related Costs		Non-GAAP3
2010
Materials and production	$	4,440	$	1,206	$	105		$	—	$	3,129
Marketing and administrative		3,579		—		13			160		3,406
Research and development		4,517		2,225		115			—		2,177
Restructuring costs		121		—		121			—		—
2009
Materials and production	$	4,901	$	2,286	$	19		$	—	$	2,596
Marketing and administrative		3,455		—		—			265		3,190
Research and development		1,971		—		(13	)		—		1,984
Restructuring costs		1,490		—		1,490			—		—

Page 5

Full Year

			Included in expenses for the period
	GAAP		Purchase Accounting Adjustments4		Restructuring Costs		Merger- Related Costs		Non-GAAP3
2010
Materials and production	$	18,396	$	6,566	$	430	$	—	$	11,400
Marketing and administrative		13,245		—		143		379		12,723
Research and development		10,991		2,441		428		—		8,122
Restructuring costs		985		—		985		—		—
2009
Materials and production	$	9,019	$	2,286	$	115	$	—	$	6,618
Marketing and administrative		8,543		—		—		371		8,172
Research and development		5,845		—		232		—		5,613
Restructuring costs		1,634		—		1,634		—		—

The gross margin was 63.3 percent for the fourth quarter and 60.0 percent for the full year of 2010, reflecting 10.8 and 15.2 percentage point unfavorable impacts, respectively, from the purchase accounting adjustments and restructuring costs noted above.

Equity income from affiliates was $171 million in the fourth quarter and $587 million for the full year of 2010. Equity income from affiliates primarily includes the AstraZeneca LP, Johnson & Johnson Merck Consumer Pharmaceuticals Company and Sanofi Pasteur MSD partnerships, and no longer reflects any contribution from the Merck/Schering-Plough partnership or from Merial Limited (Merial).

Other (income) expense, net was $309 million of expense in the fourth quarter of 2010 which includes $120 million of exchange losses due to the Venezuelan currency devaluation. Other (income) expense, net was $1.3 billion of expense for the full year of 2010, which reflects a previously disclosed $950 million legal reserve, $200 million of exchange losses due to Venezuelan currency devaluations and $443 million of income recognized upon AstraZeneca’s asset option exercise in the second quarter. Other (income) expense, net for the fourth quarter of 2009 was $7.8 billion of income primarily reflecting a $7.5 billion gain associated with obtaining a controlling interest in the Merck/Schering-Plough partnership. Other (income) expense, net for the full year of 2009 was $10.7 billion of income which included the $7.5 billion gain associated with obtaining a controlling interest in the Merck/Schering-Plough partnership, and a $3.2 billion gain from the sale of Merck’s interest in Merial.

Page 6

The GAAP effective tax rate of 28.7 percent for the fourth quarter of 2010 reflects the impact of purchase accounting adjustments, restructuring costs and merger-related costs. The non-GAAP effective tax rate, which excludes these items, was 14.1 percent for the quarter. Both the GAAP and non-GAAP effective tax rates reflect a benefit of approximately $80 million as a result of the fourth quarter 2010 enactment of the tax extenders legislation, including the R&D tax credit.

Financial Targets

The company expects full year 2011 revenue to grow in the low to mid-single digit percent range from the base of $46.0 billion in the full year 2010.

In 2011, Merck is targeting full year non-GAAP EPS in the range of $3.64 to $3.76, excluding certain items, and a 2011 GAAP EPS range of $2.05 to $2.33. The 2011 non-GAAP EPS range excludes purchase accounting adjustments, restructuring and merger-related costs.

EPS and other financial targets for 2011 assume that Merck will retain full rights to REMICADE and SIMPONI in the applicable markets. The 2011 targets also assume that the results from the animal health business will continue to be reported in net sales and operating expenses for the entire year, and these targets will be adjusted upon formation of the joint venture.

A reconciliation of anticipated 2011 EPS as reported in accordance with GAAP to non-GAAP EPS that excludes certain items is provided in the table below.

Non-GAAP research and development expense, which excludes joint ventures, is anticipated to be approximately $8.1 billion to $8.5 billion for the full year of 2011. This target excludes restructuring costs and in-process R&D impairment charges.

Merck estimates that its consolidated non-GAAP 2011 tax rate will be approximately 20 percent to 22 percent.

Given industry pressures such as greater E.U. austerity measures and the additional impact of U.S. health care reform, as well as developments in its vorapaxar clinical program, the company has withdrawn its previous long-term target of high single-digit non-GAAP EPS compound annual growth rate from 2009 to 2013.

Page 7

	Full Year 2011
GAAP EPS	$	2.05 to $2.33
EPS difference2	$	1.59 to $1.43
Non-GAAP EPS that excludes certain items, listed below	$	3.64 to $3.76
	Full Year 2011
Purchase accounting adjustments	$	4,800 to $4,500
Costs related to restructuring programs		900 to 700
Merger-related costs		200 to 100
Net decrease (increase) in income before taxes		5,900 to 5,300
Income tax (benefit) expense8 on above items		(980) to (860	)
Decrease (increase) in net income	$	4,920 to $4,440
EPS difference2	$	1.59 to $1.43

Product Performance – Human Health

Bone, Respiratory, Immunology and Dermatology

Worldwide sales of SINGULAIR (montelukast sodium), a once-a-day oral medicine indicated for the chronic treatment of asthma and the relief of symptoms of allergic rhinitis, were $1.3 billion for the fourth quarter of 2010, an increase of 7 percent compared with the fourth quarter of 2009. Full year worldwide sales for SINGULAIR were $5.0 billion, a 7 percent increase compared with the prior year.

Global sales of NASONEX (mometasone furoate monohydrate) nasal spray, an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms, were $303 million for the fourth quarter and $1.2 billion for the full year of 2010.

Sales of REMICADE (infliximab) were $710 million for the fourth quarter and $2.7 billion for the full year of 2010. REMICADE is a treatment for inflammatory diseases. Sales of SIMPONI (golimumab) were $42 million for the fourth quarter and $97 million for the full year of 2010. SIMPONI, a once-monthly, subcutaneous treatment for certain inflammatory diseases, has been launched in 18 countries and launches in other international markets are planned. A subsidiary of Merck has exclusive marketing rights for REMICADE and SIMPONI outside the United States except in China, Japan, Indonesia, Taiwan and Hong Kong. The subsidiary’s rights to market REMICADE and SIMPONI are the subject of an ongoing arbitration process with Centocor, which has been previously disclosed.

⁸ Represents an estimated income tax (benefit) expense on the reconciling items.

Page 8

Cardiovascular

Global sales of ZETIA (ezetimibe) and VYTORIN (ezetimibe/simvastatin), the company’s cholesterol-lowering medicines, were $629 million and $562 million, respectively, for the fourth quarter of 2010. Annual worldwide sales of ZETIA for 2010 were $2.3 billion and $2.0 billion for VYTORIN.

Diabetes and Obesity

JANUVIA (sitagliptin), Merck’s DPP-4 inhibitor for the treatment of type 2 diabetes, recorded worldwide sales of $675 million during the fourth quarter of 2010, representing a 21 percent increase compared with the same quarter in 2009. JANUMET (sitagliptin/metformin hydrochloride), a single tablet that targets all three key defects of type 2 diabetes, achieved worldwide sales of $288 million during the quarter, an increase of 42 percent compared with the fourth quarter 2009. The JANUVIA/JANUMET combined franchise had sales of $962 million during the fourth quarter of 2010, an increase of 27 percent compared to the same quarter in 2009. JANUVIA reached $2.4 billion in worldwide sales in 2010, while JANUMET achieved $954 million in global sales for the year. The combined JANUVIA/JANUMET franchise had sales of $3.3 billion for the full year of 2010, an increase of 29 percent.

Infectious Disease

ISENTRESS (raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, reported worldwide sales of $313 million for the fourth quarter of 2010, an increase of 34 percent compared with the fourth quarter of 2009. Global sales of ISENTRESS for the full year of 2010 were $1.1 billion, a 45 percent increase compared with the prior year.

Worldwide sales of PEGINTRON (peginterferon alfa-2b) for chronic hepatitis C were $198 million for the fourth quarter and $737 million for the full year of 2010.

Diversified Brands

Merck’s diversified brands are human health pharmaceutical products that are approaching the expiration of their marketing exclusivity or are no longer protected by patents in developed markets, but continue to be a core part of the company’s offering in other markets around the world.

Page 9

Global sales of Merck’s antihypertensive medicines, COZAAR (losartan potassium) and HYZAAR⁹ (losartan potassium and hydrochlorothiazide), were $415 million for the fourth quarter of 2010, representing a 57 percent decrease compared with the fourth quarter of 2009. Full year worldwide sales for COZAAR/HYZAAR were $2.1 billion, a 41 percent decrease compared to the full year of 2009. The company continues to experience a significant decline in COZAAR/HYZAAR sales since these medicines have lost marketing exclusivity in the United States and in major European markets.

Neuroscience and Ophthalmology

Global sales of MAXALT (rizatriptan benzoate), Merck’s tablet for the acute treatment of migraine, were $149 million for the fourth quarter of 2010, a 5 percent decrease from the same quarter last year. MAXALT reported global sales of $550 million for the full year of 2010, a 4 percent decrease from the full year 2009.

Sales of BRIDION (sugammadex), for the reversal of certain muscle relaxants during surgery, were $40 million in the fourth quarter of 2010 and $103 million for the full year of 2010. BRIDION is currently launching in more than 30 countries outside of the United States.

Oncology

Sales of TEMODAR (temozolomide), a treatment for certain types of brain tumors, were $266 million for the fourth quarter and $1.1 billion for the full year of 2010.

Global sales of EMEND (aprepitant), a treatment for chemotherapy-induced nausea and vomiting, were $110 million for the fourth quarter, an increase of 23 percent compared with the same quarter of 2009, and $378 million for full year 2010, an increase of 19 percent compared with the same period last year.

Sales of CAELYX (pegylated liposomal doxorubicin hydrochloride) for the treatment of ovarian cancer, metastatic breast cancer and Kaposi’s sarcoma, were $75 million for the fourth quarter and $284 million for the full year of 2010. As previously disclosed, marketing rights for CAELYX returned to Johnson & Johnson on Dec. 31, 2010.

Vaccines¹⁰

Total sales as recorded by Merck of its cervical cancer vaccine, GARDASIL (human papillomavirus (HPV) quadrivalent (types 6, 11, 16, 18) vaccine, recombinant), were $221 million for the fourth quarter of 2010, a 20 percent decrease from the same quarter in 2009. The decrease is primarily a result of a government purchase for the CDC Strategic National Stockpile in the fourth quarter 2009. Worldwide sales of GARDASIL for the year were $988 million, a 12 percent decrease compared with the prior year.

⁹ COZAAR and HYZAAR are registered trademarks of E.I. duPont de Nemours and Company, Wilmington, Del.

¹⁰ Vaccines in most major European markets are sold through the company’s joint venture, Sanofi Pasteur MSD, and the results from the company’s interest in the joint venture are recorded in equity income from affiliates.

Page 10

Worldwide sales of Merck’s other viral vaccines, which include VARIVAX (varicella virus vaccine live), M-M-R II (measles, mumps and rubella virus vaccine live) and PROQUAD (measles, mumps, rubella and varicella virus vaccine live), as recorded by Merck, were $285 million for the fourth quarter of 2010, a decrease of 14 percent compared with the same period a year earlier. The decrease is primarily a result of a 2009 government purchase of VARIVAX for the CDC Strategic National Stockpile. Sales of other viral vaccines for the year were $1.4 billion, an increase of 1 percent over full year 2009.

ZOSTAVAX (zoster vaccine live), the company’s vaccine to help prevent shingles (herpes zoster), recorded sales of $107 million for the fourth quarter of 2010 compared with $76 million for the fourth quarter of 2009. Sales for the full year of 2010 were $243 million compared with $277 million for 2009. Sales this quarter were driven by significant backorder fulfillment. Product backorders are expected to continue through at least the first quarter of 2011 and the company anticipates sales in future quarters will be affected by availability of supply.

Women’s Health and Endocrine

Global sales of NUVARING (etonogestrel/ethinyl estradiol) vaginal ring, a contraceptive product, were $145 million for the fourth quarter and $559 million for the full year of 2010.

Sales of FOLLISTIM AQ (follitropin beta injection), a fertility treatment, were $138 million for the fourth quarter and $528 million for the full year of 2010.

Product Performance — Animal Health

Animal Health sales totaled $815 million for the fourth quarter and $2.9 billion for the full year of 2010, reflecting continued solid performance among ruminant and swine products. Animal Health includes pharmaceutical and vaccine products for the prevention, treatment and control of disease in all major farm and companion animal species. Merck and sanofi-aventis continue the process of forming the proposed Animal Health joint venture and expect to close the transaction in the first half of 2011.

Product Performance — Consumer Care

Consumer Care sales were $251 million for the fourth quarter and $1.3 billion for the full year of 2010, which reflect continued strong performance of a number of key brands including DR. SCHOLL’s and COPPERTONE. Consumer Care includes footcare and suncare consumer products, and a variety of over-the-counter medicines.

Page 11

Total Employees

As of Dec. 31, 2010, Merck had approximately 94,000 employees worldwide.

Explanatory Note

Supplemental combined non-GAAP sales are provided on page 4 and in the attached schedules at the end of this news release to reflect the revenues of the company’s product sales on a comparable basis to periods prior to the merger. Merck has defined supplemental combined non-GAAP sales as GAAP sales adjusted to reflect a full quarter and full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in the applicable table. This supplemental information is provided to enhance investors’ understanding of the company’s products and overall business performance. This information should be considered in addition to, but not in lieu of, sales recorded in accordance with GAAP. Supplemental combined non-GAAP sales are available in Tables 3 and 3a as part of this news release, and additional information is included in the 8-K filing today.

Earnings Conference Call

Investors are invited to a live audio webcast of Merck’s fourth quarter earnings conference call today at 8:00 a.m. EST by visiting Merck’s Web site, www.merck.com/investors/events-and-presentations/home.html. Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782. Journalists are invited to listen in on the call by dialing (706) 758-9928 or (800) 399-7917. A replay of the call will be available starting at 11 a.m. EST on Feb. 3 through 11:59 p.m. EST on Feb. 11. To listen to the replay, dial (706) 645-9291 or (800) 642-1687 and enter ID No. 30176534.

About Merck

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships that donate and deliver our products to the people who need them. For more information, visit www.merck.com.

Page 12

Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2009 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

# # #

Page 13

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS - GAAP

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 1

	GAAP									GAAP
	4Q10			4Q09			% Change			Full Year 2010			Full Year 2009			% Change
Sales	$	12,094		$	10,093			20	%	$	45,987		$	27,428			68	%
Costs, Expenses and Other
Materials and production (1)		4,440			4,901			-9	%		18,396			9,019			*
Marketing and administrative (1)		3,579			3,455			4	%		13,245			8,543			55	%
Research and development (1)		4,517			1,971			*			10,991			5,845			88	%
Restructuring costs (2)		121			1,490			-92	%		985			1,634			-40	%
Equity income from affiliates (3)		(171	)		(374	)		-54	%		(587	)		(2,235	)		-74	%
Other (income) expense, net (4)		309			(7,813	)		*			1,304			(10,668	)		*
(Loss) Income Before Taxes		(701	)		6,463			*			1,653			15,290			-89	%
Income Tax (Benefit) Provision		(201	)		(60	)					671			2,268
Net (Loss) Income		(500	)		6,523			*			982			13,022			-92	%
Less: Net Income Attributable to Noncontrolling Interests		31			29						121			123
Net (Loss) Income Attributable to Merck & Co., Inc.	$	(531	)	$	6,494			*		$	861		$	12,899			-93	%
(Loss) Earnings per Common Share Assuming Dilution (5)	$	(0.17	)	$	2.35			*		$	0.28		$	5.65			-95	%
Average Shares Outstanding Assuming Dilution (6)		3,081			2,753						3,120			2,273
Tax Rate (7)		28.7	%		-0.9	%					40.6	%		14.8	%

*³ 100%

(1) Amounts include the impact of purchase accounting adjustments, restructuring costs and merger-related costs. See accompanying tables for details.

(2) Represents separation and other related costs associated with restructuring activities.

(3) In 2010, equity income from affiliates no longer reflects any contribution from the Merck/Schering-Plough partnership, which is now wholly-owned by the company as a result of the merger, or from Merial Limited due to the divesture of Merck’s interest in September 2009.

(4) Other (income) expense, net in the fourth quarter and full year of 2010 includes $120 million and $200 million, respectively, of exchange losses due to Venezuelan currency devaluations. Other (income) expense, net for the full year of 2010 also includes a $950 million legal reserve and a $443 million gain recognized upon AstraZeneca’s exercise of the asset option. Other (income) expense, net in the fourth quarter of 2009 includes a $7.5 billion gain related to the Merck/Schering-Plough partnership recognized in connection with the merger. In addition, other (income) expense, net for the full year of 2009 includes a $3.2 billion gain on the divestiture of Merck’s interest in Merial Limited. Other (income) expense, net includes merger-related costs of $17 million for the full year of 2010 and $23 million and $173 million for the fourth quarter and full year of 2009, respectively.

(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders (losses are not allocated). Net income attributable to Merck & Co., Inc. common shareholders used to calculate earnings per common share assuming dilution was $6,463 million for the fourth quarter of 2009 and was $859 million and $12,853 million for the full year of 2010 and 2009, respectively.

(6) Because the company recorded a loss in the fourth quarter of 2010, no potential dilutive common shares were used in the computation of loss per share assuming dilution as the effect would have been anti-dilutive.

(7) The GAAP effective tax rates for the fourth quarter and full year of 2010 were 28.7% and 40.6%, respectively. Excluding the impact of the non-GAAP items detailed in the accompanying tables, the effective tax rates were 14.1% and 20.0% for the fourth quarter and full year of 2010, respectively. The fourth quarter and full year of 2010 GAAP and non-GAAP effective tax rates reflect a benefit of approximately $80 million as a result of the fourth quarter 2010 enactment of the tax extenders legislation, including the R&D tax credit.

The GAAP effective tax rates for the fourth quarter and full year of 2009 were (0.9)% and 14.8%, respectively. Excluding the impact of the non-GAAP items detailed in the accompanying tables, the effective tax rates were 15.3% and 20.0% for the fourth quarter and full year of 2009, respectively. The fourth quarter and full year of 2009 GAAP and non-GAAP effective tax rates were impacted by the favorable effect of tax settlements.

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

FOURTH QUARTER 2010

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2a

	GAAP			Purchase Accounting  (1)			Restructuring Costs (2)			Merger-Related Costs (3)			Adjustment Subtotal			Non-GAAP
Sales	$	12,094											$	—		$	12,094
Materials and production		4,440			1,206			105						1,311			3,129
Marketing and administrative		3,579						13			160			173			3,406
Research and development		4,517			2,225			115						2,340			2,177
Restructuring costs		121						121						121			—
Equity income from affiliates		(171	)											—			(171	)
Other (income) expense, net		309												—			309
(Loss) Income Before Taxes		(701	)		(3,431	)		(354	)		(160	)		(3,945	)		3,244
Income Tax (Benefit) Provision		(201	)											(658	) (4)		457
Net (Loss) Income		(500	)											(3,287	)		2,787
Less: Net Income Attributable to Noncontrolling Interests		31												—			31
Net (Loss) Income Attributable to Merck & Co., Inc.	$	(531	)										$	(3,287	)	$	2,756
(Loss) Earnings per Common Share Assuming Dilution	$	(0.17	)													$	0.88	(5)
Average Shares Outstanding Assuming Dilution		3,081															3,106
Tax Rate		28.7	%														14.1	%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger. Amounts included in research and development expenses represent in-process research and development (“IPR&D”) impairment charges, including a $1.7 billion charge to write-down the intangible asset related to vorapaxar.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested.

(3) Merger-related costs include transaction and integration costs associated with the merger.

(4) Represents the estimated tax impact on the reconciling items.

(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $2,746 million for the fourth quarter of 2010.

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

FULL YEAR 2010

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2b

	GAAP			Purchase Accounting  (1)			Restructuring Costs (2)			Merger-Related Costs (3)			Certain Other Items (4)			Adjustment Subtotal			Non-GAAP
Sales	$	45,987														$	—		$	45,987
Materials and production		18,396			6,566			430									6,996			11,400
Marketing and administrative		13,245						143			379						522			12,723
Research and development		10,991			2,441			428									2,869			8,122
Restructuring costs		985						985									985			—
Equity income from affiliates		(587	)														—			(587	)
Other (income) expense, net		1,304									17			507			524			780
Income Before Taxes		1,653			(9,007	)		(1,986	)		(396	)		(507	)		(11,896	)		13,549
Taxes on Income		671															(2,042	) (5)		2,713
Net Income		982															(9,854	)		10,836
Less: Net Income Attributable to Noncontrolling Interests		121															—			121
Net Income Attributable to Merck & Co., Inc.	$	861														$	(9,854	)	$	10,715
Earnings per Common Share Assuming Dilution	$	0.28																	$	3.42	(6)
Average Shares Outstanding Assuming Dilution		3,120																		3,120
Tax Rate		40.6	%																	20.0	%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger. Amounts included in research and development expenses represent in-process research and development (“IPR&D”) impairment charges, including a $1.7 billion charge to write-down the intangible asset related to vorapaxar.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested.

(3) Merger-related costs include transaction and integration costs associated with the merger.

(4) Included in other (income) expense, net is a $950 million legal reserve and a $443 million gain recognized upon AstraZeneca’s exercise of the asset option.

(5) Includes a $391 million tax benefit from changes in a foreign entity’s tax rate, a charge of $147 million associated with a change in tax law enacted as part of U.S. health care reform legislation, as well as the estimated tax impact on the other reconciling items.

(6) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $10,673 million for the full year of 2010.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

FOURTH QUARTER 2010

(AMOUNTS IN MILLIONS)

Table 3

The following Table reflects Supplemental Combined Non-GAAP sales for the prior year which were adjusted to reflect a full quarter of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

	GAAP 4Q10		GAAP 4Q09		Adjustment 4Q09		Supp.  Comb. Non-GAAP 4Q09		% Change (4Q10 GAAP vs Supp. Comb.  Non-GAAP 4Q09)
TOTAL SALES (1)	$	12,094	$	10,093	$	2,123	$	12,216		-1
HUMAN HEALTH (2)		10,581		9,072		1,733		10,805		-2
Bone, Resp., Imm., & Dermatology
Singulair		1,349		1,260				1,260		7
Remicade		710		431		205		635		12
Nasonex		303		165		121		286		6
Fosamax		234		285				285		-18
Clarinex		146		101		55		155		-6
Arcoxia		115		98				98		17
Proventil		55		26		30		56		-2
Asmanex		53		37		21		58		-8
Cardiovascular
Zetia		629		399		215		614		2
Vytorin		562		384		194		577		-3
Integrilin		63		46		26		72		-12
Diabetes & Obesity
Januvia		675		558				558		21
Janumet		288		202				202		42
Infectious Disease
Isentress		313		234				234		34
PegIntron		198		149		67		216		-8
Cancidas		174		175				175		—
Primaxin		158		196				196		-19
Invanz		113		88				88		29
Avelox		92		66		52		118		-22
Rebetol		54		36		21		57		-4
Crixivan / Stocrin		58		52				52		11
Diversified Brands
Cozaar / Hyzaar		415		955				955		-57
Zocor		121		139				139		-13
Propecia		124		123				123		1
Claritin Rx		122		71		38		109		11
Vasotec / Vaseretic		64		85				85		-25
Remeron		62		38		21		60		5
Proscar		44		72				72		-39
Neurosciences & Ophthalmology
Maxalt		149		156				156		-5
Cosopt / Trusopt		131		134				134		-2
Subutex / Suboxone		1		36		20		56		-98
Oncology
Temodar		266		188		103		292		-9
Emend		110		89				89		23
Caelyx		75		47		24		70		7
Intron A		54		38		16		54		-1
Vaccines
ProQuad, M-M-R II and Varivax		285		333				333		-14
Gardasil		221		277				277		-20
RotaTeq		169		135				135		25
Pneumovax		156		128				128		22
Zostavax		107		76				76		41
Women’s Health & Endocrine
NuvaRing		145		88		47		135		7
Follistim AQ		138		96		53		149		-7
Implanon		71		37		16		53		34
Cerazette		49		35		18		53		-8
Other Human Health (3)		1,160		708		372		1,079		8
ANIMAL HEALTH		815		494		265		759		7
CONSUMER CARE (2)		251		149		83		232		8
Claritin OTC		67		39		25		63		6
Other Revenues (4)		447		379		41		420		6
Astra		302		332				332		-9

⁽¹⁾ Only select products are shown.

⁽²⁾ Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

⁽³⁾ Includes Human Health products not individually shown above. Other Vaccines sales included in Other Human Health were $75 million and $50 million for fourth quarter 2010 and 2009, respectively.

⁽⁴⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company’s product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full quarter of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors’ understanding of the company’s sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

FULL YEAR 2010

(AMOUNTS IN MILLIONS)

Table 3a

The following Table reflects Supplemental Combined Non-GAAP sales for the prior year which were adjusted to reflect the period of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

	GAAP Full Year  10		GAAP Full Year  09		Adjustment Full  Year 09		Supp.  Comb. Non-GAAP Full Year 09		% Change (FY 10 GAAP vs Supp. Comb. Non-GAAP FY 09)
TOTAL SALES (1)	$	45,987	$	27,428	$	18,537	$	45,964		—
HUMAN HEALTH (2)		39,811		25,236		14,862		40,098		-1
Bone, Resp., Imm., & Dermatology
Singulair		4,987		4,660				4,660		7
Remicade		2,714		431		1,896		2,327		17
Nasonex		1,220		165		1,014		1,179		3
Fosamax		926		1,100				1,100		-16
Clarinex		659		101		619		719		-8
Arcoxia		398		358				358		11
Proventil		210		26		198		225		-7
Asmanex		208		37		177		214		-3
Cardiovascular
Zetia		2,297		403		1,841		2,244		2
Vytorin		2,014		441		1,671		2,112		-5
Integrilin		266		46		249		295		-10
Diabetes & Obesity
Januvia		2,385		1,922				1,922		24
Janumet		954		658				658		45
Infectious Disease
Isentress		1,090		752				752		45
PegIntron		737		149		696		844		-13
Cancidas		611		617				617		-1
Primaxin		610		689				689		-11
Invanz		362		293				293		24
Avelox		316		66		302		368		-14
Rebetol		221		36		218		254		-13
Crixivan / Stocrin		206		206				206		—
Diversified Brands
Cozaar / Hyzaar		2,104		3,561				3,561		-41
Zocor		468		558				558		-16
Propecia		447		440				440		1
Claritin Rx		420		71		362		433		-3
Vasotec / Vaseretic		255		311				311		-18
Remeron		223		38		195		234		-5
Proscar		216		291				291		-26
Neurosciences & Ophthalmology
Maxalt		550		575				575		-4
Cosopt / Trusopt		484		503				503		-4
Subutex / Suboxone		111		36		175		211		-47
Oncology
Temodar		1,065		188		885		1,073		-1
Emend		378		317				317		19
Caelyx		284		47		219		265		7
Intron A		209		38		192		231		-9
Vaccines
ProQuad, M-M-R II and Varivax		1,378		1,369				1,369		1
Gardasil		988		1,118				1,118		-12
RotaTeq		519		522				522		-1
Pneumovax		376		346				346		9
Zostavax		243		277				277		-12
Women’s Health & Endocrine
NuvaRing		559		88		422		511		9
Follistim AQ		528		96		450		546		-3
Implanon		236		37		142		179		32
Cerazette		209		35		153		187		11
Other Human Health (3)		4,170		1,218		2,787		4,005		4
ANIMAL HEALTH		2,941		494		2,222		2,716		8
CONSUMER CARE (2)		1,342		149		1,131		1,281		5
Claritin OTC		401		39		367		406		-1
Other Revenues (4)		1,893		1,548		322		1,870		1
Astra		1,252		1,414				1,414		-11

⁽¹⁾ Only select products are shown.

⁽²⁾ Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

⁽³⁾ Includes Human Health products not individually shown above. Other Vaccines sales included in Other Human Health were $282 million and $188 million for the full year 2010 and 2009, respectively.

⁽⁴⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company’s product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect the full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors’ understanding of the company’s sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

EX-99.2

Exhibit 99.2

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

FOURTH QUARTER 2009

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2c

	GAAP			Purchase Accounting (1)			Restructuring Costs (2)			Merger-Related Costs (3)			Certain Other Items (4)			Adjustment Subtotal			Non-GAAP
Sales	$	10,093														$	—		$	10,093
Materials and production		4,901			2,286			19									2,305			2,596
Marketing and administrative		3,455									265						265			3,190
Research and development		1,971						(13	)								(13	)		1,984
Restructuring costs		1,490						1,490									1,490			—
Equity income from affiliates		(374	)														—			(374	)
Other (income) expense, net		(7,813	)								23			(7,930	)		(7,907	)		94
Income Before Taxes		6,463			(2,286	)		(1,496	)		(288	)		7,930			3,860			2,603
Taxes on Income		(60	)														(458	) (5)		398
Net Income		6,523															4,318			2,205
Less: Net Income Attributable to Noncontrolling Interests		29															—			29
Net Income Attributable to Merck & Co., Inc.	$	6,494														$	4,318		$	2,176
Earnings per Common Share Assuming Dilution	$	2.35																	$	0.79	(6)
Average Shares Outstanding Assuming Dilution		2,753																		2,753
Tax Rate		-0.9	%																	15.3	%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested.

(3) Merger-related costs include transaction and integration costs associated with the merger.

(4) Included in other (income) expense, net is a $7.5 billion gain related to the Merck/Schering-Plough partnership recognized in connection with the merger. Also included in other (income) expense, net is $400 million of additional gain on the divesture of Merck’s interest in Merial Limited which had been deferred.

(5) Represents the estimated tax impact on the reconciling items.

(6) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $2,166 million for the fourth quarter of 2009.

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

FULL YEAR 2009

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2d

	GAAP			Purchase Accounting (1)			Restructuring Costs (2)			Merger-Related Costs (3)			Certain Other Items (4)			Adjustment Subtotal			Non-GAAP
Sales	$	27,428														$	—		$	27,428
Materials and production		9,019			2,286			115									2,401			6,618
Marketing and administrative		8,543									371						371			8,172
Research and development		5,845						232									232			5,613
Restructuring costs		1,634						1,634									1,634			—
Equity income from affiliates		(2,235	)														—			(2,235	)
Other (income) expense, net		(10,668	)								173			(10,692	)		(10,519	)		(149	)
Income Before Taxes		15,290			(2,286	)		(1,981	)		(544	)		10,692			5,881			9,409
Taxes on Income		2,268															390	(5)		1,878
Net Income		13,022															5,491			7,531
Less: Net Income Attributable to Noncontrolling Interests		123															—			123
Net Income Attributable to Merck & Co., Inc.	$	12,899														$	5,491		$	7,408
Earnings per Common Share Assuming Dilution	$	5.65																	$	3.25	(6)
Average Shares Outstanding Assuming Dilution		2,273																		2,273
Tax Rate		14.8	%																	20.0	%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested.

(3) Merger-related costs include transaction and integration costs associated with the merger.

(4) Included in other (income) expense, net is a $7.5 billion gain related to the Merck/Schering-Plough partnership recognized in connection with the merger. Also included in other (income) expense, net is a $3.2 billion gain on the divesture of Merck’s interest in Merial Limited.

(5) Represents the estimated tax impact on the reconciling items.

(6) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $7,382 million for 2009.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

FOURTH QUARTER 2010

(AMOUNTS IN MILLIONS)

Table 3b

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect a full quarter of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

	Global						U.S.						International
	4Q10		Supp. Comb. Non-GAAP 4Q09		% Change		4Q10		Supp. Comb. Non-GAAP 4Q09		% Change		4Q10		Supp. Comb. Non-GAAP 4Q09		% Change
TOTAL SALES (1)	$	12,094	$	12,216		-1	$	5,224	$	5,535		-6	$	6,870	$	6,681		3
HUMAN HEALTH (2)		10,581		10,805		-2		4,400		4,740		-7		6,182		6,064		2
Bone, Resp., Imm., & Dermatology
Singulair		1,349		1,260		7		838		810		3		511		450		14
Remicade		710		635		12								710		635		12
Nasonex		303		286		6		146		157		-7		157		129		22
Fosamax		234		285		-18		25		39		-36		209		246		-15
Clarinex		146		155		-6		47		55		-14		99		100		-1
Arcoxia		115		98		17								115		98		17
Proventil		55		56		-2		53		54		-2		2		2		14
Asmanex		53		58		-8		47		55		-15		6		2		*
Cardiovascular
Zetia		629		614		2		329		343		-4		299		271		10
Vytorin		562		577		-3		296		319		-7		266		258		3
Integrilin		63		72		-12		58		67		-14		5		5		9
Diabetes & Obesity
Januvia		675		558		21		425		390		9		250		168		49
Janumet		288		202		42		164		136		21		123		66		86
Infectious Disease
Isentress		313		234		34		164		113		45		149		121		23
PegIntron		198		216		-8		35		23		54		163		193		-16
Cancidas		174		175		—		17		19		-8		157		156		1
Primaxin		158		196		-19		29		41		-31		130		155		-16
Invanz		113		88		29		50		43		18		63		45		40
Avelox		92		118		-22		86		115		-25		6		4		79
Rebetol		54		57		-4								54		57		-4
Crixivan / Stocrin		58		52		11		2		2		-20		56		50		13
Diversified Brands
Cozaar / Hyzaar		415		955		-57		9		363		-98		406		592		-31
Zocor		121		139		-13		12		10		18		109		129		-15
Propecia		124		123		1		39		38		3		85		84		1
Claritin Rx		122		109		11								122		109		11
Vasotec / Vaseretic		64		85		-25								64		85		-25
Remeron		62		60		5		1		3		-55		61		57		7
Proscar		44		72		-39		1		2		-27		43		71		-39
Neurosciences & Ophthalmology
Maxalt		149		156		-5		106		107		-1		43		49		-12
Cosopt / Trusopt		131		134		-2		5		7		-24		126		127		-1
Subutex / Suboxone		1		56		-98								1		56		-98
Oncology
Temodar		266		292		-9		109		103		7		157		189		-17
Emend		110		89		23		65		56		16		45		34		34
Caelyx		75		70		7								75		70		7
Intron A		54		54		-1		28		29		-4		26		25		2
Vaccines
ProQuad, M-M-R II and Varivax		285		333		-14		272		310		-12		13		22		-43
Gardasil		221		277		-20		157		218		-28		64		59		8
RotaTeq		169		135		25		149		123		21		21		12		69
Pneumovax		156		128		22		115		74		56		40		54		-26
Zostavax		107		76		41		107		76		41
Women’s Health & Endocrine
NuvaRing		145		135		7		86		80		8		58		55		5
Follistim AQ		138		149		-7		40		45		-10		98		105		-6
Implanon		71		53		34		24		18		36		47		36		33
Cerazette		49		53		-8								49		53		-8
Other Human Health (3)		1,160		1,079		8		263		297		-12		898		780		15
ANIMAL HEALTH		815		759		7		169		161		5		646		598		8
CONSUMER CARE (2)		251		232		8		232		214		9		18		19		-2
Claritin OTC		67		63		6		65		62		5		2		1		*
Other Revenues (4)		447		420		6		423		420		1		24				*
Astra		302		332		-9		302		332		-9

⁽¹⁾ Only select products are shown.

⁽²⁾ Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

⁽³⁾ Includes Human Health products not individually shown above. Other Vaccines sales included in Other Human Health were $75 million and $50 million on a global basis for fourth quarter 2010 and 2009, respectively.

⁽⁴⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company’s product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full quarter of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors’ understanding of the company’s sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

* 100% or over

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

FULL YEAR 2010

(AMOUNTS IN MILLIONS)

Table 3c

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect a full year of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

	Global						U.S.						International
	Full Year 2010		Supp. Comb. Non-GAAP Full Year 2009		% Change		Full Year 2010		Supp. Comb. Non-GAAP Full Year 2009		% Change		Full Year 2010		Supp. Comb. Non-GAAP Full Year 2009		% Change
TOTAL SALES (1)	$	45,987	$	45,964		—	$	20,226	$	21,269		-5	$	25,761	$	24,695		4
HUMAN HEALTH (2)		39,811		40,098		-1		16,811		17,766		-5		23,000		22,332		3
Bone, Resp., Imm., & Dermatology
Singulair		4,987		4,660		7		3,219		3,044		6		1,768		1,615		9
Remicade		2,714		2,327		17								2,714		2,327		17
Nasonex		1,220		1,179		3		639		648		-1		581		530		9
Fosamax		926		1,100		-16		93		161		-42		832		939		-11
Clarinex		659		719		-8		203		249		-19		457		470		-3
Arcoxia		398		358		11								398		358		11
Proventil		210		225		-7		202		220		-8		8		5		58
Asmanex		208		214		-3		195		204		-4		13		10		25
Cardiovascular
Zetia		2,297		2,244		2		1,227		1,296		-5		1,070		948		13
Vytorin		2,014		2,112		-5		1,077		1,219		-12		938		893		5
Integrilin		266		295		-10		245		275		-11		20		19		5
Diabetes & Obesity
Januvia		2,385		1,922		24		1,563		1,404		11		822		518		59
Janumet		954		658		45		576		472		22		378		187		*
Infectious Disease
Isentress		1,090		752		45		554		370		50		536		382		40
PegIntron		737		844		-13		98		110		-11		639		735		-13
Cancidas		611		617		-1		61		73		-16		550		543		1
Primaxin		610		689		-11		123		136		-10		487		553		-12
Invanz		362		293		24		180		152		19		182		141		29
Avelox		316		368		-14		296		353		-16		20		15		36
Rebetol		221		254		-13		1		1		3		220		253		-13
Crixivan / Stocrin		206		206		—		8		10		-24		198		196		1
Diversified Brands
Cozaar / Hyzaar		2,104		3,561		-41		400		1,321		-70		1,705		2,240		-24
Zocor		468		558		-16		42		45		-8		426		513		-17
Propecia		447		440		1		148		148		—		298		293		2
Claritin Rx		420		433		-3								420		433		-3
Vasotec / Vaseretic		255		311		-18								255		311		-18
Remeron		223		234		-5		7		10		-31		216		224		-4
Proscar		216		291		-26		6		6		1		210		285		-26
Neurosciences & Ophthalmology
Maxalt		550		575		-4		378		398		-5		173		176		-2
Cosopt / Trusopt		484		503		-4		20		39		-50		464		464
Subutex / Suboxone		111		211		-47								111		211		-47
Oncology
Temodar		1,065		1,073		-1		403		387		4		662		686		-3
Emend		378		317		19		230		202		14		147		115		28
Caelyx		284		265		7								284		265		7
Intron A		209		231		-9		114		121		-6		95		110		-13
Vaccines
ProQuad, M-M-R II and Varivax		1,378		1,369		1		1,305		1,288		1		73		81		-9
Gardasil		988		1,118		-12		722		802		-10		266		317		-16
RotaTeq		519		522		-1		439		468		-6		81		54		49
Pneumovax		376		346		9		296		245		21		80		101		-21
Zostavax		243		277		-12		243		277		-12
Women’s Health & Endocrine
NuvaRing		559		511		9		342		313		9		217		198		10
Follistim AQ		528		546		-3		167		179		-6		361		368		-2
Implanon		236		179		32		86		63		38		150		116		29
Cerazette		209		187		11								209		187		11
Other Human Health (3)		4,170		4,005		4		903		1,057		-15		3,266		2,947		11
ANIMAL HEALTH		2,941		2,716		8		616		599		3		2,326		2,117		10
CONSUMER CARE (2)		1,342		1,281		5		1,213		1,175		3		128		105		22
Claritin OTC		401		406		-1		379		390		-3		23		16		45
Other Revenues (4)		1,893		1,870		1		1,586		1,729		-8		307		141		*
Astra		1,252		1,414		-11		1,252		1,414		-11

⁽¹⁾ Only select products are shown.

⁽²⁾ Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

⁽³⁾ Includes Human Health products not individually shown above. Other Vaccines sales included in Other Human Health were $282 million and $188 million on a global basis for full year 2010 and 2009, respectively.

⁽⁴⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company’s product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors’ understanding of the company’s sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

* 100% or over

MERCK & CO., INC.

HUMAN HEALTH GEOGRAPHIC SALES

(AMOUNTS IN MILLIONS)

Table 3d

	1Q10			2Q10			3Q10			4Q10			Full Year
TOTAL HUMAN HEALTH	$	9,793		$	9,776		$	9,660		$	10,581		$	39,811
United States		4,090			4,041			4,281			4,400			16,811
% Human Health Sales		41.8	%		41.3	%		44.3	%		41.6	%		42.2	%
Europe (1)		2,831			2,660			2,360			2,690			10,541
% Human Health Sales		28.9	%		27.2	%		24.4	%		25.4	%		26.5	%
Japan		811			902			855			1,077			3,645
% Human Health Sales		8.3	%		9.2	%		8.9	%		10.2	%		9.2	%
Latin America		694			728			742			819			2,983
% Human Health Sales		7.1	%		7.4	%		7.7	%		7.7	%		7.5	%
Asia Pacific		587			659			659			755			2,659
% Human Health Sales		6.0	%		6.7	%		6.8	%		7.1	%		6.7	%
Eastern Europe/Middle East Africa		404			422			371			410			1,607
% Human Health Sales		4.1	%		4.3	%		3.8	%		3.9	%		4.0	%
Canada		337			328			374			364			1,403
% Human Health Sales		3.4	%		3.4	%		3.9	%		3.4	%		3.5	%
Other		39			37			17			67			161
% Human Health Sales		0.4	%		0.4	%		0.2	%		0.6	%		0.4	%

(1) Europe primarily represents all European Union countries and the European Union accession markets.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

Full Year 2010

(AMOUNTS IN MILLIONS)

Table 3e

	2010 - GAAP
	1Q		2Q		3Q		4Q		Full Year
TOTAL SALES (1)	$	11,422	$	11,346	$	11,125	$	12,094	$	45,987
HUMAN HEALTH (2)		9,793		9,776		9,660		10,581		39,811
Bone, Resp., Imm., & Dermatology
Singulair		1,165		1,258		1,215		1,349		4,987
Remicade		674		669		661		710		2,714
Nasonex		320		338		259		303		1,220
Fosamax		230		241		220		234		926
Clarinex		174		202		137		146		659
Arcoxia		95		95		94		115		398
Proventil		57		55		43		55		210
Asmanex		51		56		48		53		208
Cardiovascular
Zetia		534		564		571		629		2,297
Vytorin		477		490		485		562		2,014
Integrilin		70		70		63		63		266
Diabetes & Obesity
Januvia		511		600		600		675		2,385
Janumet		201		218		247		288		954
Infectious Disease
Isentress		232		267		278		313		1,090
PegIntron		186		185		168		198		737
Cancidas		153		150		135		174		611
Primaxin		159		158		135		158		610
Invanz		75		83		91		113		362
Avelox		106		59		59		92		316
Rebetol		56		55		55		54		221
Crixivan / Stocrin		52		48		49		58		206
Diversified Brands
Cozaar / Hyzaar		782		485		423		415		2,104
Zocor		116		117		114		121		468
Propecia		100		113		109		124		447
Claritin Rx		124		93		81		122		420
Vasotec / Vaseretic		59		63		69		64		255
Remeron		51		59		50		62		223
Proscar		58		56		58		44		216
Neurosciences & Ophthalmology
Maxalt		135		133		133		149		550
Cosopt / Trusopt		115		123		114		131		484
Subutex / Suboxone		52		51		7		1		111
Oncology
Temodar		274		271		254		266		1,065
Emend		84		93		91		110		378
Caelyx		74		66		70		75		284
Intron A		54		51		50		54		209
Vaccines
ProQuad, M-M-R II and Varivax		319		340		434		285		1,378
Gardasil		233		219		316		221		988
RotaTeq		93		139		119		169		519
Pneumovax		51		59		110		156		376
Zostavax		95		18		23		107		243
Women’s Health & Endocrine
NuvaRing		135		145		134		145		559
Follistim AQ		134		137		119		138		528
Implanon		51		51		64		71		236
Cerazette		55		49		56		49		209
Other Human Health (3)		974		986		1,049		1,160		4,170
ANIMAL HEALTH		709		731		687		815		2,941
CONSUMER CARE (2)		379		422		291		251		1,342
Claritin OTC		110		132		92		67		401
Other Revenues (4)		542		417		487		447		1,893
Astra		364		241		345		302		1,252

⁽¹⁾ Only select products are shown.

⁽²⁾ Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

⁽³⁾ Includes Human Health products not individually shown above. Other Vaccines sales included in Other Human Health were $55 million, $57 million, $94 million and $75 million for the first, second, third and fourth quarters of 2010, respectively.

⁽⁴⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES - SUPPLEMENTAL COMBINED NON-GAAP

FULL YEAR 2009

(AMOUNTS IN MILLIONS)

Table 3f

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect full quarters and a full year of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

	2009 - Supplemental Combined Non-GAAP
	1Q		2Q		3Q		4Q		Full Year
TOTAL SALES (1)	$	10,683	$	11,534	$	11,531	$	12,216	$	45,964
HUMAN HEALTH (2)		9,235		9,956		10,101		10,805		40,098
Bone, Resp., Imm., & Dermatology
Singulair		1,057		1,257		1,085		1,260		4,660
Remicade		518		565		608		635		2,327
Nasonex		306		321		266		286		1,179
Fosamax		261		277		276		285		1,100
Clarinex		174		226		164		155		719
Arcoxia		81		88		90		98		358
Proventil		54		56		59		56		225
Asmanex		49		54		53		58		214
Cardiovascular
Zetia		510		556		563		614		2,244
Vytorin		477		532		525		577		2,112
Integrilin		76		73		74		72		295
Diabetes & Obesity
Januvia		411		462		491		558		1,922
Janumet		128		155		173		202		658
Infectious Disease
PegIntron		216		215		198		216		844
Isentress		148		172		197		234		752
Primaxin		165		160		168		196		689
Cancidas		139		149		155		175		617
Avelox		109		71		70		118		368
Invanz		62		71		73		88		293
Rebetol		66		67		64		57		254
Crixivan / Stocrin		49		56		49		52		206
Diversified Brands
Cozaar / Hyzaar		839		906		861		955		3,561
Zocor		137		141		141		139		558
Propecia		103		106		109		123		440
Claritin Rx		132		96		95		109		433
Vasotec / Vaseretic		77		76		73		85		311
Proscar		72		79		67		72		291
Remeron		50		50		74		60		234
Neurosciences & Ophthalmology
Maxalt		133		141		144		156		575
Cosopt / Trusopt		121		125		123		134		503
Subutex / Suboxone		50		52		53		56		211
Oncology
Temodar		247		256		278		292		1,073
Emend		69		77		82		89		317
Caelyx		61		68		67		70		265
Intron A		54		67		56		54		231
Vaccines
ProQuad, M-M-R II and Varivax		252		322		462		333		1,369
Gardasil		262		268		311		277		1,118
RotaTeq		134		126		127		135		522
Pneumovax		41		47		130		128		346
Zostavax		75		42		84		76		277
Women’s Health & Endocrine
Follistim AQ		131		145		122		149		546
NuvaRing		115		129		131		135		511
Cerazette		39		46		49		53		187
Implanon		37		43		45		53		179
Other Human Health (3)		945		965		1,016		1,079		4,005
ANIMAL HEALTH		621		672		664		759		2,716
CONSUMER CARE (2)		384		381		283		232		1,281
Claritin OTC		149		108		85		63		406
Other Revenues (4)		443		524		483		420		1,870
Astra		356		386		340		332		1,414

⁽¹⁾ Only select products are shown.

⁽²⁾ Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

⁽³⁾ Includes Human Health products not individually shown above. Other Vaccines sales included in Other Human Health were $50M in 1Q09, $34M in 2Q09, $54M in 3Q09, and $50M in 4Q09, respectively.

⁽⁴⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company’s product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors’ understanding of the company’s sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

MERCK & CO., INC.

EQUITY INCOME / JV SALES / OTHER (INCOME) EXPENSE - GAAP

FOURTH QUARTER 2010

Table 4

EQUITY INCOME FROM AFFILIATES (millions of dollars)

	4Q10			4Q09		FY 2010		FY 2009
ASTRAZENECA LP	$	190		$	192	$	546	$	674
MERCK / SCHERING-PLOUGH (1)		—			151		—		1,195
Other (2)		(19	)		31		41		366
TOTAL	$	171		$	374	$	587	$	2,235

⁽¹⁾ Upon completion of the merger with Schering-Plough, the Merck/Schering-Plough partnership became wholly-owned by the company.

⁽²⁾ Primarily reflects results for Merial Limited (which was disposed of on September 17, 2009), Sanofi Pasteur MSD and Johnson & JohnsonºMerck Consumer Pharmaceuticals.

SANOFI PASTEUR MSD JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.

	4Q10		4Q09		FY 2010		FY 2009
GARDASIL	$	106	$	132	$	350	$	549
FLU VACCINES		62		82		220		249
OTHER VIRAL VACCINES		27		33		93		112
ROTATEQ		9		13		42		42
HEPATITIS VACCINES		7		9		25		44
Other Vaccines		135		167		487		593
TOTAL SANOFI PASTEUR MSD SALES	$	346	$	436	$	1,217	$	1,589

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	4Q10			4Q09			FY 2010			FY 2009
INTEREST INCOME	$	(27	)	$	(11	)	$	(83	)	$	(210	)
INTEREST EXPENSE		177			169			715			460
EXCHANGE LOSSES (GAINS)		130			(9	)		214			(12	)
Other, net (1)		29			(7,962	)		458			(10,906	)
TOTAL	$	309		$	(7,813	)	$	1,304		$	(10,668	)

⁽¹⁾ Other, net for the full year of 2010 primarily reflects a $950 million legal reserve and a $443 million gain recognized upon AstraZeneca’s exercise of the asset option. Other, net for the fourth quarter and full year of 2009 primarily reflects a $7.5 billion gain associated with the Merck/Schering-Plough partnership. In addition, the full year of 2009 also reflects a $3.2 billion gain on the sale of Merck’s interest in Merial Limited.